Pharmafile - Medical Communications News
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a recent...
-Samsung BioLogics delisted from Korean Stock Exchange-No-deal prep a waste of time, Welsh ABPI says -Alabama insurer won't cover oxycontin -NICE say...
German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel...
US pharma firm United Therapeutics has agreed to by Arena Pharmaceuticals experimental pulmonary arterial hypertension (PAH) drug ralinepag in a...
Ipsen’s Cabometyx has received approval from the European Commission for Cabometyx (cabozantinib) as a monotherapy for the treatment of...
The Association of the British Pharmaceutical Industry (ABPI) has responded to Theresa May’s Brexit deal, after the government announced a 585 page...
American pharma firm Pfizer have lost in the final round of a protracted court battle over the patent on epilepsy drug Lyrica, after Britain’s...
To mark this year’s World Diabetes Day on 14 November, a new report has shed more light on the psychological impact of type 1 and 2 diabetes,...
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now be used...
Check out this week’s top ten most popular stories on Pharmafile.com!
